Unsaturated Hydroxamic Acid Derivatives and Their Use for the Treatment and Prevention of an Ammonia-Associated Disease or Disorder
US-2024293344-A1 · Sep 5, 2024 · US
US9757546B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9757546-B2 |
| Application number | US-201213729974-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 28, 2012 |
| Priority date | Jun 26, 2009 |
| Publication date | Sep 12, 2017 |
| Grant date | Sep 12, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another.
Opening claim text (preview).
We claim: 1. A solid drug unit comprising: a drug in the form of a mini-tablet which is greater than 70% by weight the drug, with the balance being at least one excipient, wherein the mini-tablet is cylindrical with flat end faces, the length of the tablet exceeding its diameter so that the mini-tablet has an aspect ratio of greater than 1:1, wherein the mini-tablet has a diameter from 1.0 mm to 3.2 mm and a length from 1.7 mm to 4.8 mm, such that the mini-tablet is sized and shaped for insertion through the urethra of a patient, wherein the friability of the mini-tablet is less than 2%, and wherein the mini-tablet is sterilized. 2. The solid drug unit of claim 1 , wherein the mini-tablet has a diameter from 1.5 mm to 3.1 mm and a length from 2.0 mm to 4.5 mm. 3. The solid drug unit of claim 1 , wherein the drug is between 70 wt % and 99 wt % of the mini-tablet. 4. The solid drug unit of claim 1 , wherein the drug is an anesthetic agent, and antimicrobial agent, or a chemotherapeutic agent. 5. The solid drug unit of claim 4 , wherein the excipient comprises a binder and a lubricant. 6. The solid drug unit of claim 1 , wherein the drug comprises lidocaine. 7. The solid drug unit of claim 1 , wherein the mini-tablet is between 85 wt % and 95 wt % lidocaine.
Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants · CPC title
Anaesthetics · CPC title
of the bladder · CPC title
Local anaesthetics · CPC title
Solids · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.